Clinical Trial: " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06983756) titled '" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "' on May 14.

Brief Summary: The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).

Study Start Date: June 01

Study Type: OBSERVATIONAL

Condition: Erythropoietin Resistant Anemia (EPO Resistant Anemia)

Intervention: DRUG: Erythropoietin

EPO resistance

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Fayoum University ...